Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 5
2014 6
2015 1
2016 2
2017 3
2018 2
2019 2
2020 3
2021 1
2022 4
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Biomarker signatures for progressive idiopathic pulmonary fibrosis.
Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, Maher TM, Navaratnam V, Hubbard R, Hopkins PMA, Reynolds PN, Chapman S, Zappala C, Keir GJ, Cooper WA, Mahar AM, Ellis S, Goh NS, De Jong E, Cha L, Tan DBA, Leigh L, Oldmeadow C, Walters EH, Jenkins RG, Moodley Y. Clynick B, et al. Among authors: keir gj. Eur Respir J. 2022 Mar 31;59(3):2101181. doi: 10.1183/13993003.01181-2021. Print 2022 Mar. Eur Respir J. 2022. PMID: 34675050
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM. Saunders P, et al. Among authors: keir gj. Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2. Trials. 2017. PMID: 28619061 Free PMC article. Clinical Trial.
Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis.
Humphries SM, Mackintosh JA, Jo HE, Walsh SLF, Silva M, Calandriello L, Chapman S, Ellis S, Glaspole I, Goh N, Grainge C, Hopkins PMA, Keir GJ, Moodley Y, Reynolds PN, Walters EH, Baraghoshi D, Wells AU, Lynch DA, Corte TJ. Humphries SM, et al. Among authors: keir gj. Respirology. 2022 Dec;27(12):1045-1053. doi: 10.1111/resp.14333. Epub 2022 Jul 25. Respirology. 2022. PMID: 35875881 Free PMC article.
Circulating RNA differences between patients with stable and progressive idiopathic pulmonary fibrosis.
Clynick B, Jo HE, Corte TJ, Glaspole IN, Grainge C, Hopkins PMA, Reynolds PN, Chapman S, Walters EH, Zappala C, Keir GJ, Cooper WA, Mahar AM, Ellis S, Goh NS, Baltic S, Ryan M, Tan DBA, Moodley YP. Clynick B, et al. Among authors: keir gj. Eur Respir J. 2020 Sep 10;56(3):1902058. doi: 10.1183/13993003.02058-2019. Print 2020 Sep. Eur Respir J. 2020. PMID: 32381494 Free article. No abstract available.
Rituximab in severe, treatment-refractory interstitial lung disease.
Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA. Keir GJ, et al. Respirology. 2014 Apr;19(3):353-9. doi: 10.1111/resp.12214. Epub 2013 Nov 29. Respirology. 2014. PMID: 24286447
Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.
Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, Symons K, Spencer LM, Reynolds PN, Chapman S, de Boer S, Reddy T, Holland AE, Chambers DC, Glaspole IN, Jo HE, Bleasel JF, Wrobel JP, Dowman L, Parker MJS, Wilsher ML, Goh NSL, Moodley Y, Keir GJ. Jee AS, et al. Among authors: keir gj. Respirology. 2021 Jan;26(1):23-51. doi: 10.1111/resp.13977. Epub 2020 Nov 24. Respirology. 2021. PMID: 33233015 Free PMC article.
27 results